Welcome back to the State Trade Podcast, everyone.

I'm Tim Bowen, back with Matt McCall and get another very interesting big picture idea.

And I think like, especially timeframe-wise, this might be one of the biggest things we see short term.

Like obviously AI, we've talked a lot about AI.

You're going to hear us talk more about AI.

But that's still kind of building up, you know, finding its way.

But I see something that's happening right now.

And I'm sure many of you might know and maybe your users as well is, is what I call them the GLP-1s, you know, the Ozympics, the Migenos, et

cetera, you know, these medications that are allowing people to just lose a massive amount

of weight and feel better about themselves and be more productive. So like, you know, when I talk about this,

a big diet and exercise guy, you guys know that, but like I know a lot of people, especially

you're really busy, you got a lot going on. It can be difficult to, you know, to fix the diet

and get all that exercise in. And listen, we all know if you're overweight, low energy, you know

you're less productive.

You're not going to get as much done.

And that's why I want to ask Matt to talk about this is I saw, I'll probably misquote it,

but like I saw a Goldman Sachs article where they're talking about just like the ridiculous

amount of economic impact of these things and not just the sales you know not to just no more

nor noticing etc but the productivity enhancements and again if you guys know me i'm all on

optimization and read all these self-help books and like that's what gives me excite and i just like

the idea of more productive people more happy people and that's what excites me about these. Now, before I bring back, come in, listen, I don't know.

Like one thing I will say is I don't know the long term effects of these things.

...